References
- Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75-87. https://doi.org/10.1016/s0140-6736(18)30696-2
- Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm. 2013;2013:165974. https://doi.org/10.1155/2013/165974
- Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003;3:169-176. https://doi.org/10.1038/nri1004
- Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock. 2000;13:110-116. https://doi.org/10.1097/00024382-200013020-00004
- Monsalve E, Ruiz-Garcia A, Baladron V, Ruiz-Hidalgo MJ, Sanchez-Solana B, Rivero S, et al. Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity. Eur J Immunol. 2009;39:2556-2570. https://doi.org/10.1002/eji.200838722
- Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 2014;13:741-758. https://doi.org/10.1038/nrd4368
- Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-2064. https://doi.org/10.1056/nejmoa1202290
- Chen W, Mook RA Jr, Premont RT, Wang J. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018;41:89-96. https://doi.org/10.1016/j.cellsig.2017.04.001
- Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018-1036. https://doi.org/10.1093/jnci/djr190
- Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012;11:1703-1712. https://doi.org/10.1158/1535-7163.mct-12-0002
- Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett. 2010;1:454-459. https://doi.org/10.1021/ml100146z
- Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1-15. https://doi.org/10.1016/j.cytogfr.2016.05.001
- Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994;77:63-71. https://doi.org/10.1016/0092-8674(94)90235-6
- Hilliard KL, Allen E, Traber KE, Kim Y, Wasserman GA, Jones MR, et al. Activation of hepatic STAT3 maintains pulmonary defense during endotoxemia. Infect Immun. 2015;83:4015-4027. https://doi.org/10.1128/iai.00464-15
- Huang W, Huang L, Wen M, Fang M, Deng Y, Zeng H. Long non-coding RNA DILC is involved in sepsis by modulating the signaling pathway of the interleukin-6/signal transducer and activator of transcription 3/Toll-like receptor 4 axis. Mol Med Rep. 2018;18:5775-5783. https://doi.org/10.3892/mmr.2018.9559
- Fang X, Abbott J, Cheng L, Colby JK, Lee JW, Levy BD, et al. Human mesenchymal stem (stromal) cells promote the resolution of acute lung injury in part through lipoxin A4. J Immunol. 2015;195:875-881. https://doi.org/10.4049/jimmunol.1500244
- Cao Z, Liao Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: the way forward? Cancer Lett. 2019;459:30-40. https://doi.org/10.1016/j.canlet.2019.05.025
- Fleischmann-Struzek C, Mikolajetz A, Schwarzkopf D, Cohen J, Hartog CS, Pletz M, et al. Challenges in assessing the burden of sepsis and understanding the inequalities of sepsis outcomes between National Health Systems: secular trends in sepsis and infection incidence and mortality in Germany. Intensive Care Med. 2018;44:1826-1835. https://doi.org/10.1007/s00134-018-5377-4
- Su BC, Huang HN, Lin TW, Hsiao CD, Chen JY. Epinecidin-1 protects mice from LPS-induced endotoxemia and cecal ligation and puncture-induced polymicrobial sepsis. Biochim Biophys Acta Mol Basis Dis. 2017;1863:3028-3037. https://doi.org/10.1016/j.bbadis.2017.08.032
- Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18:596. https://doi.org/10.1186/s13054-014-0596-8
- Moriyama K, Nishida O. Targeting cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns in sepsis via blood purification. Int J Mol Sci. 2021;22:8882. https://doi.org/10.3390/ijms22168882
- Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. 2018;36:247-277. https://doi.org/10.1146/annurev-immunol-051116-052415
- Beyer D, Hoff J, Sommerfeld O, Zipprich A, Gassler N, Press AT. The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation. Mol Med. 2022;28:84. https://doi.org/10.1186/s10020-022-00510-8
- Meng A, Zhang X, Shi Y. Role of p38 MAPK and STAT3 in lipopolysaccharide-stimulated mouse alveolar macrophages. Exp Ther Med. 2014;8:1772-1776. https://doi.org/10.3892/etm.2014.2023
- Xia T, Zhang M, Lei W, Yang R, Fu S, Fan Z, et al. Advances in the role of STAT3 in macrophage polarization. Front Immunol. 2023;14:1160719. https://doi.org/10.3389/fimmu.2023.1160719
- Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol. 2017;198:1006-1014. https://doi.org/10.4049/jimmunol.1601515
- Matsukawa A, Takeda K, Kudo S, Maeda T, Kagayama M, Akira S. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J Immunol. 2003;171:6198-6205. https://doi.org/10.4049/jimmunol.171.11.6198